Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Inmune Bio total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Inmune Bio's total debt was $2.49M at Sep 30, 2024. For fiscal 2023 it was $9.92M, down 32.5% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $9.92M | -32.5% |
| FY2022 | Dec 31, 2022 | $14.70M | +1987.6% |
| FY2021 | Dec 31, 2021 | $704.00K | +340.0% |
| FY2020 | Dec 31, 2020 | $160.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | $2.49M | +480.0% |
| Q2 FY2024 | Jun 30, 2024 | $4.98M | +975.4% |
| Q1 FY2024 | Mar 31, 2024 | $7.46M | -49.3% |
| Q4 FY2023 | Dec 31, 2023 | $9.92M | +1534.4% |
| Q3 FY2023 | Sep 30, 2023 | $430.00K | -33.3% |
| Q2 FY2023 | Jun 30, 2023 | $463.00K | -32.3% |
| Q4 FY2022 | Dec 31, 2022 | $14.70M | +1987.6% |
| Q3 FY2022 | Sep 30, 2022 | $607.00K | -95.8% |
| Q2 FY2022 | Jun 30, 2022 | $645.00K | +303.1% |
| Q1 FY2022 | Mar 31, 2022 | $684.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $704.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $14.35M | – |
| Q4 FY2020 | Dec 31, 2020 | $160.00K | – |
See a number that looks wrong?